IMMP
Immutep Limited
stockNASDAQADR
immutep is a globally active biotechnology company, listed on the australian stock exchange and on the nasdaq global market in the us. as a leader in personalized bio-therapeutic products for cancer, immutep is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. immutep's main pipeline of products is based on the lag-3 immune control mechanism which plays a vital role in the regulation of the t cell immune response. the most clinically advanced product is a t cell immunostimulatory factor (apc activator), imp321, for cancer chemoimmunotherapy which has completed early phase ii trials. a number of additional lag-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 3.57 | 2026-10-13 | -9.52% | -0.010 |
| 1M | 5.83 | 2026-09-21 | -44.56% | 1.591 |
| 3M | 8.15 | 2026-07-20 | -60.38% | 1.509 |
| 6M | 12.33 | 2026-04-20 | -73.81% | 0.526 |
| 1Y | 40.80 | 2025-10-20 | -92.08% | 0.661 |
| 2Y | 38.70 | 2024-10-21 | -91.65% | — |
| 5Y | 86.00 | 2021-10-20 | -96.24% | 0.080 |
Immutep Limited (NASDAQ:IMMP) stock price today is $3.23, and today's volume is 14,454. IMMP is up 1.893% today. The 30 day average volume is 25,105. IMMP market cap is $23.80M with 7.37M shares outstanding.